Dicerna’s latest deal lands $200M, Roche as partner in HBV

A year after completing a pair of deals in the span of a week, Dicerna has partnered a Phase I HBV asset with Roche in an RNAi deal that brings in $200 million up front. The partnership continues the company’s string of partnerships in therapeutic areas outside of its scope, allowing it

Read the full 523 word article

User Sign In